Author: Hans Rosenberg

Author

  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, assistant professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts
stroke
Featured, Journal Club, Neurology

Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study

by Hans Rosenberg 0 comments on Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study
Methodology: 4/5           Usefulness: 4/5 Perry JJ, et al. BMJ. 2021 Feb 4;372:n49. doi: 10.1136/bmj.n49. Question and methods: This multicenter prospective... Read more.
COPD
Journal Club, Respirology

Pharmacologic Therapies in Patients With Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-analysis.

by Hans Rosenberg 0 comments on Pharmacologic Therapies in Patients With Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-analysis.
Methodology: 4/5           Usefulness: 4.5/5 Dobler CC, et al. Ann Intern Med. 2020 Mar 17;172(6):413-422.  Questions & Methods: Systematic review of 68... Read more.
child cough
Infectious Disease, Journal Club, Pediatrics

Delayed Antibiotic Prescription for Children With Respiratory Infections: A Randomized Trial

by Hans Rosenberg 0 comments on Delayed Antibiotic Prescription for Children With Respiratory Infections: A Randomized Trial
Methodology: 3/5 Usefulness: 1/5 Mas-Dalmau G, et al. Pediatrics. 2021 Mar;147(3):e20201323. doi: 10.1542/peds.2020-1323. Question and Methods: This RCT assessed... Read more.
budesonide
COVID-19, Infectious Disease, Journal Club, Respirology

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.

by Hans Rosenberg 0 comments on Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Methodology: 2.5/5 Usefulness: 2/5 Ramakrishnan S, et al. Lancet Respir Med. 2021 Apr 9:S2213-2600(21)00160-0. Question and Methods: Is inhaled budesonide an effective... Read more.